The abstract is read at the publisher; the summary is JClub's.
Upregulating connexin43 in BRAF-mutant melanoma cells increases mitochondrial biogenesis, OXPHOS, and ROS, yet BRAF/MEK inhibition largely suppresses these stress markers while boosting mitochondrial ROS.
- Why it matters: Targeted BRAF/MEK therapy reshapes mitochondrial metabolism, but how connexin43-driven mitochondrial remodeling relates to therapeutic sensitization remains unclear.
- What they did: The study tested connexin43 upregulation in BRAF-mutant melanoma cells, measuring mitochondrial biogenesis (CI/CV), OXPHOS, ROS, DRP1 fragmentation, respiratory chain changes, ER/mitochondrial stress, and mTORC1-linked signaling, then assessed effects under BRAF/MEK inhibition.
- The result: BRAF/MEK inhibition attenuated connexin43-linked biogenesis and most stress markers, promoted mitochondrial network elongation, and increased mitochondrial ROS, while connexin43-expressing cells retained higher membrane potential, ROS, and survival under glucose limitation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.